Brief: Oxigene to advance fosbretabulin in two late-stage clinical trials
29/09/2015 21:05
Sept 29 (Reuters) - OXiGENE Inc OXGN.O : * Announces plans to advance ca4p (fosbretabulin) in two late-stage clinical trials * Says plans to conduct two new phase 2/3 randomized studies in ovarian cancer and glioblastoma multiforme * Source text for Eikon ID:nGNXVENGFa * Further company coverage OXGN.O ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Oncotelic Therapeutics
See all newsBrief: Oncotelic Therapeutics Emerging As Leader With New Independent JV Valuation
Brief: Oncotelic Therapeutics - JV Is Preparing For A Potential Initial Public Offering On The Hong Kong Stock Exchange In Late 2026
Brief: Oncotelic Therapeutics To Sell Its Necroptosis Cancer Therapy Assets To Mosaic Immunoengineering
Brief: Oncotelic Announces Initiation Of Clinical Study In Non-Small Lung Cell Cancer
Brief: Oncotelic Initiates Clinical Trials Evaluating Ot-101 Against Pediatric Gliomas